Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean r bagheri (2 results)?
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
Minson A, Verner E, Giri P, Butler J, Janowski W, Cheah CY, Ratnasingam S, Wong SM, Ku M, Hertzberg M, Herbert K, Hamad N, Yannakou CK, Swain F, Neeson P, Steiner TM, Saghebi J, Blombery P, Hunter SM, Robertson M, Lau LS, Bennett R, Harrop S, Xie J, Seymour JF, Dickinson MJ. Minson A, et al. J Clin Oncol. 2025 Jun 18:JCO2500481. doi: 10.1200/JCO-25-00481. Online ahead of print. J Clin Oncol. 2025. PMID: 40532125
We report the investigator-initiated, phase II COALITION trial of the CD20xCD3 bispecific antibody glofitamab combined with R-CHOP or Pola-R-CHP in younger patients with HR features, designed to minimize time between diagnosis and treatment. METHODS: Patients age 65 …
We report the investigator-initiated, phase II COALITION trial of the CD20xCD3 bispecific antibody glofitamab combined with R-CHOP or …
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V, Lee ST, Scott AM, Martin AJ, Stockler MR, Donnellan G, Annala M, Herberts C, Davis ID, Hofman MS, Azad AA, Wyatt AW; TheraP Investigators and the ANZUP Cancer Trials Group. Kwan EM, et al. Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03704-9. Online ahead of print. Nat Med. 2025. PMID: 40425844
Evaluation of Psychopathology and Quality of Life in Patients with Anogenital Wart Compared to Control Group.
Nahidi M, Nahidi Y, Saghebi A, Kardan G, Jarahi L, Aminzadeh B, Shojaei P, Bordbar MRF. Nahidi M, et al. Iran J Med Sci. 2018 Jan;43(1):65-69. Iran J Med Sci. 2018. PMID: 29398753 Free PMC article.
All participants were provided with the symptom checklist 90-R (SCL-90-R) and short-form (SF-36) questionnaires. All analyses were performed using the SPSS software, version 16.0.1 for Windows. ...
All participants were provided with the symptom checklist 90-R (SCL-90-R) and short-form (SF-36) questionnaires. All analyses …
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.
Kashyap R, Alipour R, Boehm E, Jewell K, RaviKumar AS, Cardin A, Saghebi J, Hofman MS, Fahey MT, Michael M, Akhurst T, Hicks RJ, Kong G. Kashyap R, et al. Eur J Nucl Med Mol Imaging. 2025 Mar 26. doi: 10.1007/s00259-025-07235-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40137978
AIM: Patients with gastro-entero-pancreatic neuroendocrine tumours (GEP NET) who retain somatostatin receptor (SSTR) expression after initial response to [(177)Lu]Lu-DOTA-Octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) are amenable to re-treatment (R-PRRT) …
AIM: Patients with gastro-entero-pancreatic neuroendocrine tumours (GEP NET) who retain somatostatin receptor (SSTR) expression after initia …